Avoid succinylcholine due to prolonged paralysis risk with cholinesterase inhibition
Rocuronium preferred neuromuscular blocker
Bronchospasm therapies
Inhaled beta agonist adjunct
Atropine as primary secretion and bronchospasm driver control
Fluids and hemodynamics
Isotonic crystalloid bolus for hypotension
Vasopressor support if refractory after atropinization
Norepinephrine infusion for persistent shock
Antidotes
Antimuscarinic therapy
Atropine
Adult IV bolus
Initial 1 mg to 3 mg IV
If no improvement in secretions, double dose every 3 to 5 minutes
Endpoint
Drying of bronchial secretions
Improved oxygenation and ventilation
Pediatric IV bolus
0.02 mg/kg IV
Minimum 0.1 mg
Maximum single dose 2 mg
Infusion after stabilization
Start 10% to 20% of total effective loading dose per hour
Titrate every 5 to 15 minutes to secretion control
Wean when stable without recurrent bronchorrhea
Adverse effects monitoring
Hyperthermia
Ileus
Urinary retention
Delirium
Cholinesterase reactivation
Pralidoxime
Indications
Suspected organophosphate exposure
Fasciculations or weakness
Respiratory failure
Adult dosing
2 g IV over 20 to 30 minutes
Repeat 2 g in 1 hour if ongoing weakness or secretions
Maintenance infusion 500 mg per hour to 1 g per hour
Pediatric dosing
25 mg/kg IV over 20 to 30 minutes
Maximum 2 g
Maintenance infusion 10 mg/kg per hour to 20 mg/kg per hour
Timing considerations
Earlier use before aging for many organophosphates
Continued benefit for ongoing exposure or persistent paralysis
Carbamate considerations
Routine use controversial
Consider if severe nicotinic features and high suspicion of organophosphate cannot be excluded
Seizure control and neuroprotection
Benzodiazepines
Diazepam IV
5 mg to 10 mg IV
Repeat every 5 to 10 minutes to seizure control
Lorazepam IV
2 mg to 4 mg IV
Repeat once to twice as needed
Pediatric lorazepam IV
0.1 mg/kg IV
Maximum 4 mg
Refractory seizure pathway
Levetiracetam IV 60 mg/kg
Maximum 4500 mg
Monitoring and endpoints
Response targets
Secretions controlled
Dry lung fields on auscultation
Reduced suction requirement
Ventilation stabilized
Improving PaCO2 mmHg
Improving ETCO2 trend
Neuromuscular recovery
Reduced fasciculations
Improving strength
Complication prevention
Aspiration precautions
Head of bed elevation
Early airway protection when needed
Temperature management
External cooling if hyperthermia
Evidence framing
Atropine titration to drying secretions supported by expert consensus
Oxime therapy for organophosphate associated weakness supported by toxicology consensus and multiple observational datasets
Benzodiazepines for seizure control consistent with Class I seizure management principles
Special Populations
Pregnancy
Pregnancy considerations
Maternal stabilization priority
Oxygenation optimization
Aggressive secretion control
Antidote use
Atropine use when clinically indicated
Pralidoxime use when organophosphate suspected
Fetal considerations
Continuous fetal monitoring for viable gestation when feasible
Obstetrics consultation early for moderate to severe cases
Geriatric
Older adult considerations
Lower physiologic reserve
Earlier respiratory failure
Higher aspiration risk
Atropine adverse effects sensitivity
Delirium risk
Urinary retention risk
Disposition bias
Lower threshold for admission and monitoring
Pediatrics
Pediatric considerations
Higher risk of dermal absorption
Larger surface area to mass ratio
Faster decompensation
Dosing safety
Weight based atropine and pralidoxime dosing
Minimum atropine dose to avoid paradoxical bradycardia
Safeguarding
Child protection involvement for unsafe storage concerns
Background
Epidemiology
Population patterns
Common global pesticide poisoning exposure in agricultural settings
Higher intentional self poisoning burden in some regions
Seasonal clustering with farming cycles
Pathophysiology
Mechanism of toxicity
Acetylcholinesterase inhibition
Acetylcholine accumulation at synapses
Muscarinic overstimulation
Nicotinic overstimulation
CNS overstimulation
Organophosphate aging
Time dependent increased stability of enzyme inhibition
Reduced oxime effectiveness after aging for some agents
Carbamate reversibility
Spontaneous hydrolysis common
Often shorter duration
Therapeutic Considerations
Antidote logic
Atropine blocks muscarinic receptors
Secretion control as primary endpoint
Heart rate normalization as secondary effect
Oximes restore enzyme activity when feasible
Greatest benefit for nicotinic weakness and paralysis
Early administration preferred for many organophosphates
Seizure control reduces hypoxia and rhabdomyolysis risk
Intermediate syndrome awareness
Delayed weakness after initial stabilization
Proximal muscle weakness
Respiratory muscle weakness
Need for prolonged monitoring in significant poisonings
Patient Discharge Instructions
copy discharge instructions
Discharge counseling
Exposure avoidance
Do not return to contaminated area until cleaned and ventilated
Wash skin and hair again at home if any residue concern
Launder exposed clothing separately in hot wash
Return to ED now
Trouble breathing
Wheezing
Persistent cough with frothy sputum
New or worsening weakness
Confusion
Seizure
Vomiting that does not stop
Slow heart rate or fainting
Follow up
Primary care within 24 to 72 hours if symptoms occurred
Occupational medicine follow up for workplace exposures
Poison center contact information provided if available locally
References
Clinical guidelines and evidence sources
Core toxicology references
Poison control center consultation standards for pesticide poisoning management
WHO pesticide poisoning guidance documents for organophosphate management
ATSDR medical management guidelines for organophosphate compounds
Goldfrank’s Toxicologic Emergencies sections on organophosphates and carbamates
Evidence and consensus framing
Atropine titration to bronchorrhea control supported by toxicology consensus
Pralidoxime use in organophosphate poisoning supported by mixed trial data and expert consensus
Benzodiazepines first line for toxin associated seizures supported by emergency neurology standards
Internal project source citation
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.